5-Year Follow-Up Confirms Health-Related QOL Benefit With Nivolumab/Ipilimumab in Advanced RCC
February 25th 2022The immunotherapy combination of nivolumab and ipilimumab elicited favorable health-related quality of life responses compared with sunitinib in patients with advanced renal cell carcinoma.
Olaparib Is Linked With Decreased Pain Burden in Metastatic Castration-Resistant Prostate Cancer
February 25th 2022Compared with enzalutamide or abiraterone acetate tablets, olaparib was associated with decreased pain burden and better health-related quality of life in patients with castration-resistant prostate cancer.
63rd American Society of Hematology Annual Meeting and Exposition: Major Nurse Takeaways
February 12th 2022Oral Bruton tyrosine kinase inhibitors make notable strides in CLL treatment. Chimeric antigen receptor T-cell therapy continues to command attention by besting standard-of-care therapies.